ClinicalTrials.gg
CompletedNCT05737485Updated Apr 29, 2025

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects

A Phase 1 interventional study of RCT1100 in Primary Ciliary Dyskinesia, sponsored by ReCode Therapeutics. Completed at 4 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by ReCode Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Ciliary Motility Disorders with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Ciliary Motility Disorders · United States.

Started
2023
with 4 others
Phase 1
3 of 28
none open now
Registered
22nd of 28
by date
Lead sponsor
4 of 28
ReCode Therapeutics

Among the 28 studies in Ciliary Motility Disorders with a site in United States, this one is one of 5 that started in 2023, is one of 3 in phase 1, and was the 22nd registered.

Ciliary Motility Disorders

80 studies on the registry are indexed under Ciliary Motility Disorders; 27 are open to participants now.

Browse Ciliary Motility Disorders studies →

Open to participants now

9 of the 28 studies in Ciliary Motility Disorders with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Ciliary Motility Disorders studies recruiting now, 15 (71%) set no upper age limit and 3 (14%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Ciliary Motility Disorders with a site in United States, or all of them as a file.
02

Study summary

This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.

Read the detailed description

The primary objective of this study is to assess the safety and tolerability of a single ascending dose of inhaled RCT1100 administered via nebulizer to healthy participants and patients with Primary Ciliary Dyskinesia caused by a pathogenic mutation in the DNAI1 Gene.

03

Conditions studied

  • Primary Ciliary Dyskinesia

Keywords

  • Primary Ciliary Dyskinesia
  • PCD
  • Kartagener Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • Healthy, adult, male or female of, 18-75 years of age, inclusive, at screening.
  • Participant has disease causing mutations in the DNAI1 gene
  • The participant has a (FEV1) of at least 50% predicted.

Major Exclusion Criteria:

  • History or presence of medical, surgical, clinical laboratory, or psychiatric condition or disease.
  • History of cancer, with exception of adequately treated basal cell or squamous cell carcinoma of the skin.
  • Medically significant hemoptysis
  • Anticoagulation therapy for the treatment of a pulmonary embolus or has had a pulmonary embolus in the last 6 months of screening.
  • Active tuberculosis infection.
  • Laboratory abnormalities in clinical laboratory tests at screening:

    1. Serum creatinine level
    2. Total , or alanine aminotransferase values
    3. Hematological or coagulation values outside the normal reference range
  • Any medical history of disease that has the potential to cause a rise in total bilirubin over the
  • History of alcohol abuse or drug addiction with the last year of screening.
  • Active smoker (vaping included).

Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    RCT1100

    Drug: RCT1100 single dose

    Drug: RCT1100

Interventions

  • RCT1100 mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer

06

What researchers measure

Primary outcomes

  1. The number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs).

    Safety and tolerability as assessed by number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs), as well as an adverse event of special interest (AESI): "Fever", which will include body temperature and any associated symptoms (chills, myalgia).

    Time frame: From Baseline Through Day 180

07

Study locations

4 sites
  • PPD - Las Vegas Research Unit
    Las Vegas, Nevada 89113, United States
  • Macquarie University
    Sydney, New South Wales 2109, Australia
  • New Zealand Clinical Research
    Auckland, New Zealand
  • Royal Brompton Hospital
    London, SW3 6NP, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Jul 2024, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2023
First posted
Feb 21, 2023
StartActual
Feb 18, 2023
Primary completionActual
Jul 25, 2024
CompletionActual
Jan 13, 2025
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05737485
Lead sponsor
ReCode Therapeutics
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
Feb 18, 2023
Primary completion
Jul 25, 2024
Completion
Jan 13, 2025
Last update
Apr 29, 2025

Study contacts

John Matthews, MBBS, MCRP, PhD
study chair · ReCode Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RCT1100

Start the discussion